Shu Taishen announced that the subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. pharmaceutical Bojianing added clinical trial applications for treatment of major surgical bleeding. The application was recently accepted by the State Drug Administration. The acceptance number is CXSL2601019. The application stage is clinical.

Shu Taishen announced that the subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. pharmaceutical Bojianing added clinical trial applications for treatment of major surgical bleeding. The application was recently accepted by the State Drug Administration. The acceptance number is CXSL2601019. The application stage is clinical.